{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,2]],"date-time":"2022-04-02T18:52:30Z","timestamp":1648925550525},"reference-count":5,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","journals.elsevierhealth.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1016\/j.eururo.2016.10.016","type":"journal-article","created":{"date-parts":[[2016,10,25]],"date-time":"2016-10-25T09:46:30Z","timestamp":1477388790000},"page":"139-140","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Re: Intravesical Bacillus Calmette-Gu\u00e9rin Versus Combination of Epirubicin and Interferon-\u03b12a in Reducing Recurrence of Non\u2013Muscle-invasive Bladder Carcinoma: FinnBladder-6 Study"],"prefix":"10.1016","volume":"71","author":[{"given":"Marc C.","family":"Colombel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2016.10.016_bib0030","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.eururo.2015.02.022","volume":"68","author":"Jarvinen","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2016.10.016_bib0035","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1097\/01.ju.0000150425.09317.67","article-title":"Bacillus Calmette-Guerin versus epirubicin for primary, secondary or concurrent carcinoma in situ of the bladder: results of a European Organization for the Research and Treatment of Cancer\u2013Genito-Urinary Group phase III trial (30906)","volume":"173","author":"de Reijke","year":"2005","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2016.10.016_bib0040","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/S0022-5347(05)67707-5","article-title":"Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study","volume":"163","author":"Lamm","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2016.10.016_bib0045","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.eururo.2009.12.024","volume":"57","author":"Sylvester","year":"2010","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2016.10.016_bib0050","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.eururo.2016.03.034","article-title":"Intravesical bacillus Calmette-Gu\u00e9rin versus combination of epirubicin and interferon-\u03b12a in reducing recurrence of non\u2013muscle-invasive bladder carcinoma: FinnBladder-6 study","volume":"70","author":"Marttila","year":"2016","journal-title":"Eur Urol"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283816307199?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283816307199?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,7]],"date-time":"2018-09-07T04:25:42Z","timestamp":1536294342000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283816307199"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":5,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["S0302283816307199"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2016.10.016","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2017,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Re: Intravesical Bacillus Calmette-Gu\u00e9rin Versus Combination of Epirubicin and Interferon-\u03b12a in Reducing Recurrence of Non\u2013Muscle-invasive Bladder Carcinoma: FinnBladder-6 Study","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2016.10.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 European Association of Urology. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}